ResMed Secures Significant Victory in Patent Fight Against New York University
December 11 2023 - 4:05PM
ResMed (NYSE: RMD, ASX: RMD) announced that it has secured a
significant victory after the United States Patent Trial and
Appeals Board (PTAB) invalidated the claims New York University
(NYU) asserted against ResMed, based on seven NYU patents.
In June 2021, NYU filed a complaint for patent infringement
against ResMed in the United States District Court, District of
Delaware. NYU’s complaint alleged that the AutoSetTM and AutoRampTM
features of ResMed’s AirSenseTM 10 AutoSet flow generators,
infringed one or more claims of seven NYU patents.
ResMed filed petitions with the PTAB asserting that all the
claims asserted against ResMed were invalid. In rulings issued from
December 4 to December 7, 2023, the PTAB judges, agreeing with
ResMed’s arguments, found that all the challenged claims across the
seven patents were invalid.
“At ResMed, we’re committed to providing patients with our
leading therapy solutions. Our sustained investment in research and
development for over 30 years has culminated in more than 9,500
issued or pending patents and designs,” said Mick Farrell, ResMed’s
CEO. “We applaud the PTAB’s ruling and will defend our innovations,
ensuring patients continue to receive our therapy solutions,
empowering them to live healthier, higher-quality lives.”
“We will continue to vigorously defend our innovations,” said
Michael Rider, ResMed’s Global General Counsel and Secretary. “The
fact that our intellectual property contributed to this victory is
a testament to our investment in research and development, the hard
work of our inventors, and the patent protection we pursue to
protect our innovation.”
About ResMedAt ResMed (NYSE: RMD, ASX: RMD), we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software platforms
support the professionals and caregivers who help people stay
healthy in the home or care setting of their choice. By enabling
better care, we improve quality of life, reduce the impact of
chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more,
visit ResMed.com and follow @ResMed.
For media |
For investors |
+1 619.510.1281 |
+1 858.836.5000 |
news@resmed.com |
investorrelations@resmed.com |
ResMed (NYSE:RMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ResMed (NYSE:RMD)
Historical Stock Chart
From Apr 2023 to Apr 2024